Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMAndARPI: AAA617 +/- ARPI in PSMA-Positive mCRPC
NCT06894511Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lutetium lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Novartis. Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs) up to 1.5 years. Started Sep 2025; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06894511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06894511.